Allen Mooney & Barnes Investment Advisors LLC Makes New $477,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Allen Mooney & Barnes Investment Advisors LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 6,132 shares of the medical device company’s stock, valued at approximately $477,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Whale Capital LLP raised its position in DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after buying an additional 113,000 shares during the last quarter. Taylor Frigon Capital Management LLC increased its stake in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after acquiring an additional 11,075 shares during the period. Brooktree Capital Management purchased a new position in DexCom during the third quarter worth about $683,000. National Pension Service lifted its position in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. purchased a new stake in DexCom in the 3rd quarter valued at approximately $650,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DXCM. Wells Fargo & Company increased their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Royal Bank of Canada reduced their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Raymond James reduced their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $98.00.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $79.17 on Wednesday. The company has a market cap of $30.92 billion, a P/E ratio of 47.41, a PEG ratio of 2.36 and a beta of 1.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The business’s 50-day simple moving average is $77.33 and its 200 day simple moving average is $78.35. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.